Stocks · News reference
Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $55 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Zenas BioPharma announced on September 15, 2026, that its Compensation Committee granted inducement stock options to purchase 53,700 shares and 98,900 restricted stock units to newly hired employees. The stock options have a 10-year term with an exercise price of $31.93 per share and vest over four years, while RSUs vest equally over four years through 2030.
ZENAS BIOPHARMA, INC.Up to 7,000,000 Shares of Common StockThis prospectus relates to the resale or other disposition from time to time of up to 7,000,000 shares (the "Shares") of our common stock, par value
Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight and raises the price target from $22 to $32.